Background MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer,
including exon 14 skipping and point mutations, have been attracting the attention of …

Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer
genome sequencing can retrospectively delineate the genetic basis of drug resistance, but …

Biologically active small molecules have a central role in drug development, and as
chemical probes and tool compounds to perturb and elucidate biological processes. Small …

High-risk neuroblastoma is often distinguished by amplification of MYCN and loss of
differentiation potential. We performed high-throughput drug screening of epigenetic …

In the last decade we have witnessed tremendous advances in our understanding of the
landscape of the molecular alterations that underpin many of the most prevalent cancers, in …

Current genome-wide screens allow system-wide study of drug resistance but detecting
small nucleotide variants (SNVs) is challenging. Here, we use chemical mutagenesis, drug …

Introduction The survival of patients with EGFR mutation-positive lung cancer has
dramatically improved since the introduction of EGFR tyrosine kinase inhibitors (EGFR …

Neoadjuvant chemotherapy (NACT) remains an attractive alternative for controlling locally
advanced cervical cancer. However, approximately 15–34% of women do not respond to …

Background: We aimed at exploring biological functions of differentially expressed miRNAs
during carcinogenesis, to identify miRNAs dysegulations involved in DNA repair …

Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively
characterised, the way these traits are achieved through the accumulation of somatic …